The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kholodova N.B.

Sotnikov V.M.

Russian Scientific Center of Roentgeno-Radiology, Moscow, Russia

Dobrovolskaya N.Y.

Federal State Budgetary Institution «Federal Center of Traumatology, Orthopedics and endoprosthesis replacement» of Ministry of Health of the Russian Federation, Cheboksary, Russia

Ponkratova Iu.A.

Rossiĭskiĭ nauchnyĭ tsentr rentgenoradiologii Minzdrava RF, Moskva

Aspects of encephalopathy in oncologic patients after chemotherapy

Authors:

Kholodova N.B., Sotnikov V.M., Dobrovolskaya N.Y., Ponkratova Iu.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(12): 84‑88

DOI: 10.17116/jnevro201411412184-88

Views: 10116

Downloaded: 197

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Kholodova NB, Sotnikov VM, Dobrovolskaya NY, Ponkratova IuA. Aspects of encephalopathy in oncologic patients after chemotherapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(12):84‑88. (In Russ.)
https://doi.org/10.17116/jnevro201411412184-88

 
МСФ на ЯМ
Close metadata
Recommended articles:
Features of the clinical and neuroimaging picture in patients with early-onset Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):56-63
Differential diagnosis of epileptogenic substrates of unknown etiology using a modi­fication of the routine MRI protocol. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):83-91
Neuroimaging predictors of hemo­rrhagic transformation of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12-2):34-38

Objective. To study clinical presentations and neuroimaging results in post chemotherapy encephalopathy. Material and methods. We examined 27 patients with cancer after chemotherapy (n=16) or chemoradiation (n=11). Results and conclusion. All patients complained of memory impairment, sluggish mentality, moderate headache, fatigue, sleep disorder, irritability. Their neurologic status included different organic symptoms. Post chemotherapy encephalopathy is characterized by the combination of severe cerebral asthenia and different organic neurologic symptoms with moderate cephalgic syndrome. MRT showed single and multiple loci of gliosis in the white matter.

Keywords:

complications after chemotherapy of oncologic diseases
encephalopathy
neuroimaging

Authors:

Kholodova N.B.

Sotnikov V.M.

Russian Scientific Center of Roentgeno-Radiology, Moscow, Russia

Dobrovolskaya N.Y.

Federal State Budgetary Institution «Federal Center of Traumatology, Orthopedics and endoprosthesis replacement» of Ministry of Health of the Russian Federation, Cheboksary, Russia

Ponkratova Iu.A.

Rossiĭskiĭ nauchnyĭ tsentr rentgenoradiologii Minzdrava RF, Moskva

List of references:

  1. Ahles T.A., Saykin A.J., Furstenberg C.T., Cole B., Mott L.A., Skalla K., Whedon M.B., Bivens S., Mitchell T., Greenberg E.R., Silberfarb P.M. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20: 485-493.
  2. Brezden C., Phillips K.-A., Bunston T., Tannock I.F. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000; 18: 2695-2701.
  3. Joshi G., Sultana R., Tangpong J., Cole M.P., St Clair D.K., Vore M., Estus S., Butterfield D.A. Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free Radic Res 2005; 39: 11: 1147-1154.
  4. Komaki R., Meyers C.A., Shin D.M., Garden A.S., Byrne K., Nickens J.A., Cox J.D. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys 1995; 33: 1: 179-182.
  5. Schagen S.B., van Dam F., Muller M.J., Boogerd W., Lindeboom J., Bruning P.F. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85: 640-650.
  6. Van Dam F.S.A.M., Schagen S.B., Muller M.J., Boogerd W., van der Wall E., Droogleever Fortuyn M.E., Rodenhuis S. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. J Nat Cancer Inst 1998; 90: 210-218.
  7. Wefel J.S., Lenzi R., Theriault R.L., Davis R.N., Meyers C.A. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Cancer 2004; 100: 2292-2299.
  8. Wieneke M.H., Dienst E.R. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 1995; 4: 61-66.
  9. Winocur G., Vardy J., Binns M.A., Kerr L., Tannock I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav 2006; 85: 1: 66-75.
  10. Ahles T.A., Tope D.M., Furstenberg C., Hann D., Mills L. Psychologic and neuropsychologic impact of autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1457-1462.
  11. Bender C.M., Sereika S.M., Berga S.L., Vogel V.G., Brufksy A.M., Paraska K.K., Ryan C.M. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology 2006; 15: 422-430.
  12. Berglund G., Bolund C., Fornander T., Rutqvist L.E., Sjoden P. Late effects of adjuvant chemotherapy on quality of life among breast cancer patients. Eur J Cancer 1991; 27: 1075-1081.
  13. Castellon S.A., Ganz P.A., Bower J.E., Petersen L., Abraham L., Greendale G.A. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clini Exp Neuropsychol 2004; 26: 955-969.
  14. Gottschalk L.A., Holcombe R.F., Jackson D., Bechtel R.J. The effects of anticancer chemotherapeutic drugs on cognitive function and other neuropsychiatric dimensions in breast cancer patients. Methods Find Exp Clin Pharmacol 2003; 25: 117-122.
  15. Hurria A., Rosen C., Hudis C., Zuckerman E., Panageas K.S., Lachs M.S., Witmer M., van Gorp W.G., Fornier M., D'Andrea G., Moasser M., Dang C., Van Poznak C., Hurria A., Holland J. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: A pilot prospective longitudinal study. J Am Geriatr Soc 2006; 54: 925-931.
  16. Jenkins V., Shilling V., Deutsch G., Bloomfield D., Morris R., Allan S., Bishop H., Hodson N., Mitra S., Sadler G., Shah E., Stein R., Whitehead S., Winstanley J. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Brit J Cancer 2006; 94: 828-834.
  17. Mar Fan H.G., Houédé-Tchen N., Yi Q.-L., Chemerynsky I., Downie F.P., Sabate K., Tannock I.F. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 2005; 31: 8025-8032.
  18. Scherwath A., Mehnart A., Schleimer B., Schirmer L., Fehlauer F., Kreienberg R., Metzner B., Thiel E., Zander A.R., Schulz-Kindermann F., Koch C. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol 2006; 17: 415-423.
  19. Servaes P., Verhagen C., Bleijenberg G. Relations between fatigue, neuropsychological functioning, and physical activity after treatment for breast carcinoma: Daily self-report and objective behavior. Cancer 2002; 95: 2017-2026.
  20. Shilling V., Jenkins V., Morris R., Deutsch G., Bloomfield D. The effects of adjuvant chemotherapy on cognition in women with breast cancer - preliminary results of an observational longitudinal study. Breast 2005; 14: 142-150.
  21. Stewart A., Collins B., MacKenzie J., Tomiak E., Verma S., Bielajew C. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psycho-Oncology 2007; 17: 1-9.
  22. Tchen N., Juffs H.G., Downie F.P., Yi Q.-L., Hu H., Chemerynsky I., Clemons M., Crump M., Goss P.E., Warr D., Tweedale M.E., Tannock I.F. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003; 21: 4175-4183.
  23. Wagner L.I., Sweet J.J., Butt Z., Desai J., Beaumont J., Havlin K.A., Cella D. Cognitive Impairment Associated with Chemotherapy for Breast Cancer: An Exploratory Case-Control Study. Abstract Presented at American Society of Clinical Oncology Clinical Science Symposium, Cognitive Impairment in Cancer Survivors; Atlanta, GA, USA 2006.
  24. Collins B., Mackenzie J., Stewart A., Bielajew C., Verma S. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psycho-Oncology 2009; 18: 134-143.
  25. Dietrich J., Han R., Yang Y., Mayer-Prschel M., Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006; 5: 7: 22.
  26. Carole S. Scherling and andra smith. Opening up the window into "Chemobrain": A neuroimaging review sensors (Basel) 2013; 13: 3: 3169-3203. Published online 2013 March 6.
  27. Brown M.S., Stemmer S.M., Simon J.H., Stears J.C., Jones R.B., Cagnoni P.J., Sheeder J.L. White matter disease induced by high-dose chemotherapy: Longitudinal study with MR imaging and proton spectroscopy. Amer J Neuroradiol 1998; 19: 217-221.
  28. Inagaki M., Yoshikawa E., Matsuoka Y., Sugawara Y., Nakano T., Akechi T., Wada N., Imoto S., Murakami K., Uchitomi Y. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007; 109: 146-156.
  29. McDonald B.C., Conroy S.K., Ahles T.A., West J.D., Saykin A.J. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat 2010; 123: 819-828.
  30. Logothetis N.K., Wandell B.A. Interpreting the BOLD signal. Annu Rev Physiol 2004; 66: 735-769.
  31. Kreukels B.P., Schagen S.B., Ridderinkhof K.R., Boogerd W., Hamburger H.L., van Dam F.S. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 2005; 94: 53-61.
  32. Kreukels B.P., Schagen S.B., Ridderinkhof K.R., Boogerd W., Hamburger H.L., Muller M.J., van Dam F.S. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: An electrophysiologic study. Clin Breast Cancer 2006; 7: 67-78.
  33. Silverman D.H.S., Dy C.J., Castellon S.A., Lai J., Pio B.S., Abraham L., Waddell K., Petersen L., Phelps M.E., Ganz P.A. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007; 103: 303-311.
  34. Kwong K.K., Belliveau J.W., Chesler D.A., Goldberg I.E., Weisskoff R.M., Poncelet B.P., Kennedy D.N., Hoppel B.E., Cohen M.S., Turner R. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Nat Acad Sci USA 1992; 89: 5675-5679.
  35. McAllister T.W., Sparling M.B., Flashman L.A., Guerin S.J., Mamourian A.C., Saykin A.J. Differential working memory load effects after mild traumatic brain injury. NeuroImage 2001; 14: 1004-1012.
  36. Saykin A.J., McDonald B.C., Ahles T., Chesnut L.A., Wang P.J., Furstenberg C.T., Horrigan S.A., Mamourian A.C. Altered Brain Activation Following Systemic Chemotherapy for Breast Cancer: Interim Analysis from a Prospective fMRI Study. Abstract presented at 34th Annual Meeting of the International Neuropsychological Society; Boston, MA, USA 2006.
  37. Kesler S.R., Bennett F.C., Mahaffey M.L., Spiegel D. Regional brain activation during verbal declarative memory in metastatic breast cancer. Clin Cancer Res 2009; 15: 6665-6673.
  38. Schagen S.B., Muller M.J., Boogerd W., Rosenbrand R.M., van Rhijn D., Rodenhuis S., van Dam F.S.A.M. Late effects of adjuvant chemotherapy on cognitive function: A follow-up study in breast cancer patients. Ann Oncol 2002; 132: 1387-1397.
  39. Shilling V., Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 2007; 11: 6-15.
  40. Starkman M.N., Gebarski S.S., Berent S., Schteingart D.E. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome. Biol Psychiatry 1992; 32: 756-765.
  41. McEwen B.S. Stress and the aging hippocampus. Front Neuroendocrinol 1999; 20: 49-70.
  42. Pruessner J.C., Baldwin M.W., Dedovic K., Renwick R., Mahani N.K., Lord C., Meaney M., Lupien S. Self-esteem, locus of control, hippocampal volume, and cortisol regulation in young and old adulthood. NeuroImage 2005; 28: 815-826.
  43. Mar Fan H.G., Houédé-Tchen N., Yi Q.-L., Chemerynsky I., Downie F.P., Sabate K., Tannock I.F. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 2005; 31: 8025-8032.
  44. Servaes P., Verhagen C., Bleijenberg G. Relations between fatigue, neuropsychological functioning, and physical activity after treatment for breast carcinoma: Daily self-report and objective behavior. Cancer 2002; 95: 2017-2026.
  45. Chang J., Couture F.A., Young S.D., Lau C.Y., McWatters K.L. Weekly administration of epoietin alfa improves cognition and quality of life in patients with breast cancer receiving chemotherapy. Support Canc Ther 2004; 2: 52-58.
  46. Jacobsen P.B., Garland L.L., Booth-Jones M., Donovan K.A., Thors C.L., Winters E., Grendys E. Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manage 2004; 28: 7-18.
  47. Massa E., Madeddu C., Lusso M.R., Gramignano G., Mantovani G. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning, and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit Rev Oncol Hematol 2006; 57: 175-182.
  48. O'Shaughnessy J.A., Vukelja S.J., Holmes F.A., Savin M., Jones M., Royall D., George M., Von Hoff D. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 2005; 5: 439-446.
  49. O'Shaughnessy J. Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 2002; 3: 116-120.
  50. Shilling V., Jenkins V., Fallowfield L., Howell A. The effects of oestrogens and anti-oestrogens on cognition. Breast 2001; 10: 484-491.
  51. Bender C.M., Paraska K.K., Sereika S.M., Ryan C.M., Berga S.L. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: A critical review. J Pain Symptom Manage 2001; 21: 407-424.
  52. Henderson V.W. Estrogen, cognition, and a woman's risk of Alzheimer's disease. Amer J Med 1997; 103: 11-18.
  53. McEwen B.S., Alves S.E. Estrogen actions in the central nervous system. Endocrine Rev 1999; 20: 279-307.
  54. Sherwin B.B. Estrogen and cognitive functioning in women. Endocr Rev 2003; 24: 133-151.
  55. Maki P.M., Dumas J. Mechanisms of action of estrogen in the brain: insights from human neuroimaging and psychopharmacologic studies. Semin Reprod Med 2009; 27: 250-259.
  56. Vardy J., Booth C., Pond G.R., Zhang H., Galica J., Dhillon H., Clarke S.J., Tannok I.F. Cytokine levels in patients with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function. J Clin Oncol 2007; 25: 9070.
  57. Kesler S., Janelsins M., Kooyakkattu D., Palesh O., Mustian K., Morrow G., Dhabhar F.S. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun 2012; doi: 10.1016/j.bbi.2012.05.017.
  58. Semenova A.I. Kardio- i neirotoksichnost' protivoopukholevykh preparatov (patogenez, klinika, profilaktika, lechenie). Prakticheskaya onkologiya 2009; 10: 3: 168-176.
  59. Shakirova I.N. Neirotoksichnost' sovremennykh tsitostatikov. Materialy VI Rossiiskogo onkologicheskogo kongressa. M 2002.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.